Edition:
United States

Tapimmune Announces Enrollment Of First Patient In Phase 2 Clinical Trial For Treating Triple-Negative Breast Cancer


Tuesday, 12 Dec 2017 06:30am EST 

Dec 12 (Reuters) - Tapimmune Inc ::TAPIMMUNE ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 2 CLINICAL TRIAL FOR TREATING TRIPLE-NEGATIVE BREAST CANCER FUNDED BY U.S. DEPARTMENT OF DEFENSE.TAPIMMUNE INC - 280-PATIENT PHASE 2 TRIAL, SPONSORED BY MAYO CLINIC, RECEIVED $13.3 MILLION IN GRANT FUNDING FROM U.S. DEPARTMENT OF DEFENSE.TAPIMMUNE - ‍INTERIM IMMUNOGENICITY RESULTS FROM ONGOING STUDY EVALUATING TPIV200 IN RANDOMIZED DOSING TRIAL IN TNBC ANTICIPATED IN FIRST HALF OF 2018.